

## Pharmaceutical Policies Updates Effective September 1, 2021

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at **mvphealthcare.com** and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** Denotes a new policy
- **Updated** Updated policies have content changes that may affect coverage criteria for services and/or drugs
- Reviewed/No Changes Policies that have been reviewed but have no content change
- Archived Denotes a policy that is no longer active

The following policies are effective September 1, 2021 and will be available for viewing on or before August 1, 2021. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Select Injectables for Asthma	Updated
Idiopathic Pulmonary Fibrosis	Updated
Cystic Fibrosis (Select Agents for Inhalation)	Updated
Cystic Fibrosis (Select Oral Agents)	Updated
Intranasal Corticosteroids	Archived
Medicare Transition Policy for 2022 (effective January 1, 2022)	Reviewed
Pain Medications	Updated
Preventive Services	Updated
Proton Pump Inhibitor Therapy	Updated
Quantity Limits for Prescription Drugs	Updated
Dupixent	New
Onychomycosis	Updated
Medicaid/HARP Medication Therapy Management Program	Archived
Benlysta	Archived
Mepron	Archived
Minocycline ER	Archived
Weight Loss Agents	Archived
Atopic Dermatitis	Archived

To view all communications, visit mvphealthcare.com/FastFax

To receive future FastFax messages by email, contact your Professional Relations Representative

